Browse by Person

Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | No Grouping
Number of items: 8.

Article

Popat, R, Brown, SR, Flanagan, L et al. (10 more authors) (2019) Extended follow‐up and the feasibility of Panobinostat maintenance for patients with Relapsed Multiple Myeloma treated with Bortezomib, Thalidomide, Dexamethasone plus Panobinostat (MUK six open label, multi‐centre phase I/II Clinical Trial). British Journal of Haematology, 185 (3). pp. 573-578. ISSN 0007-1048

Striha, A orcid.org/0000-0003-3363-8417, Ashcroft, AJ, Hockaday, A et al. (12 more authors) (2018) The role of ixazomib as an augmented conditioning therapy in salvage autologous stem cell transplant (ASCT) and as a post-ASCT consolidation and maintenance strategy in patients with relapsed multiple myeloma (ACCoRd [UK-MRA Myeloma XII] trial): study protocol for a Phase III randomised controlled trial. Trials, 19. 169. p. 169. ISSN 1745-6215

Popat, R, Brown, SR, Flanagan, L et al. (9 more authors) (2016) Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial. The Lancet Haematology, 3 (12). e572-e580. ISSN 2352-3026

Parrish, C, Morris, CTCM, Williams, CD et al. (13 more authors) (2016) Stem Cell Harvesting after Bortezomib-Based Reinduction for Myeloma Relapsing after Autologous Transplantation: Results from the British Society of Blood and Marrow Transplantation/United Kingdom Myeloma Forum Myeloma X (Intensive) Trial. Biology of Blood and Marrow Transplantation, 22 (6). pp. 1009-1016. ISSN 1083-8791

Brown, S, Hinsley, S orcid.org/0000-0001-6903-4688, Ballesteros, M et al. (11 more authors) (2016) The MUK five protocol: a phase II randomised, controlled, parallel group, multi-centre trial of carfilzomib, cyclophosphamide and dexamethasone (CCD) vs. cyclophosphamide, bortezomib (Velcade) and dexamethasone (CVD) for first relapse and primary refractory multiple myeloma. BMC hematology, 16. p. 14. ISSN 2052-1839

Schey, S, Brown, SR, Tillotson, A-L et al. (13 more authors) (2015) Bendamustine, thalidomide and dexamethasone combinationtherapy for relapsed/refractory myeloma patients: results ofthe MUKone randomized dose selection trial. British Journal of Haematology, 170 (3). pp. 336-348. ISSN 0007-1048

Dennis, M, Culligan, D, Karamitros, D et al. (8 more authors) (2013) Lenalidomide monotherapy and in combination with cytarabine, daunorubicin and etoposide for high-risk myelodysplasia and acute myeloid leukaemia with chromosome 5 abnormalities. Leukemia Research Reports, 2 (2). pp. 70-74. ISSN 2213-0489

Proceedings Paper

Yong, KL, Brown, S, Hinsley, S orcid.org/0000-0001-6903-4688 et al. (8 more authors) (2015) Carfilzomib, Cyclophosphamide and Dexamethasone Is Well Tolerated in Patients with Relapsed/Refractory Multiple Myeloma Who Have Received One Prior Regimen. In: Blood. 57th ASH Annual Meeting and Exposition, 05-08 Dec 2015, Orlando, FL, USA. American Society of Hematology .

This list was generated on Sun Nov 24 21:11:25 2019 GMT.